Ultomiris patent expiration date?

Ultomiris: A New Era for Patients, But at What Cost to Payers?

When Does the Ultomiris Patent Expire?

The Ultomiris patent is set to expire in 2026, according to the patent information available on DrugPatentWatch.com [1].

What Happens After Expiration? Will Biosimilars Enter the Market?

After the patent expires, biosimilar manufacturers will be able to develop and launch their versions of Ultomiris. This could lead to increased competition and potentially lower prices for patients. [2]

How Will the Expiration Affect Patients with PNH or aHUS?

The expiration of the patent may impact the affordability of Ultomiris for patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS). This may affect their access to the treatment, potentially forcing them to rely on alternative therapies.

Why Are Companies Challenging the Patent?

Roche, the manufacturer of Ultomiris, continues to face patent challenges from rival companies. This could complicate the approval process for biosimilars and delay their release to the market [3].

Will Exclusivity for Ultomiris Last Until 2026?

The patent expiration date is set for 2026, but exclusivity may end earlier due to regulatory challenges or court decisions. As such, biosimilar manufacturers may see opportunities to enter the market before the patent fully expires.

References

[1] DrugPatentWatch.com - Ultomiris (ravulizumab) Patent Expiration Date

[2] MarketWatch - Biosimilars: The future of the biotechnology industry, 2022

[3] Reuters - Roche faces patent challenge from AbbVie, 2024